Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is a antimalarial combination presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It treats and prevents malaria infection, including acute uncomplicated Plasmodium falciparum malaria, in travelers and patients at risk.

GNH USA supplies Malarone as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial drug used for both prophylaxis and treatment of malaria infections. - Prevention of malaria infection (chemoprophylaxis): provides protective effect for travelers to endemic regions. - Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears parasitemia and resolves symptoms. - Prevention of malaria in individuals exposed to drug‑resistant strains: reduces risk of infection when resistance to other agents is documented.

Malarone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Abdominal pain: cramping or discomfort in the stomach area. - Diarrhoea: loose stools that resolve after a few days. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Hepatic enzyme elevation: may indicate liver stress. - Hypersensitivity reactions (including anaphylaxis): rare but potentially life‑threatening. - Blood dyscrasias (e.g., neutropenia, thrombocytopenia): monitor blood counts if symptoms arise. - Severe abdominal pain with fever: could signal serious infection.

Before prescribing Malarone, clinicians should consider several safety factors. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh maternal benefit against infant risk. - Renal impairment: dose adjustment may be required in severe dysfunction. - Hepatic impairment: use with caution; monitor liver function tests. - Drug resistance: ensure adherence to full course to minimise resistance development. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Malarone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations. - Cimetidine: may increase atovaquone exposure, raising toxicity risk. - Protease inhibitors (e.g., ritonavir): can alter metabolism of both components.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium: decrease atovaquone absorption; separate dosing by at least 2 hours. - Warfarin: potential for increased INR; monitor coagulation parameters. - Macrolide antibiotics (e.g., erythromycin): may raise proguanil levels; observe for enhanced side effects.